 IRVINE, Calif., April 26, 2021 GLOBE NEWSWIRE -- Eledon Pharmaceuticals, Inc. Eledon NASDAQ: ELDN, a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis ALS, today announced an updated development strategy for AT-1501 in renal transplantation. 